The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

To whom it may concern:

November 10, 2020
CompanyTakara Bio Inc.

Headquarters

Nojihigashi 7-4-38, Kusatsu, Shiga 525-0058, Japan

Representative

Koichi Nakao, President & CEO

Contact

Takuya Kakemi, General Manager of Corporate

Telephone(+81)77-565-6970

Websitehttps://www.takara-bio.co.jp/(First Section of the TSE, code: 4974)

Management Division, Executive Officer

Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
Kusatsu/Shiga, Japan-November 10, 2020 – Takara Bio Inc. (Takara Bio), today announced the revision of theconsolidated financial forecast that was disclosed on August 4, 2020 and the dividend forecast for the fiscal year
ending March 31, 2021 (April 1, 2020 – March 31, 2021) that was disclosed on May 14, 2020, as follows basedon a review of current trends in results of operations.
1. Revision to Financial Forecast(1) Revision to the Consolidated Forecast for the fiscal year ending March 31, 2021(April 1, 2020 – March 31, 2021)
Operating profit

Ordinary profit

Net income
attributable toowners of parent

Net income pershare

Million yen

Million yen

Million yen

Million yen

Yen

39,600

6,500

6,600

4,000

33.22

Revised forecast (B)40,800

8,000

8,100

5,000

41.52

Amount of Change (B-A)

1,200

1,500

1,500

1,000－

Percentage of change (%)(Reference) Results forthe previous fiscal year
ended March 31, 2020

3.0

23.1

22.7

25.0－

34,565

6,274

6,347

3,819

31.72

Net sales

Previous forecast (A)(2) Reason of the Revision

As for the consolidated forecasts, the Company has revised the financial forecast disclosed on August
4, 2020, considering results for the six months ended September 30, 2020 and recent progress in ourbusiness. Net sales of research reagents and scientific instruments are expected to exceed previous
forecasts, mainly due to strong demand for PCR testing-related products due to the new Coronavirus
disease pandemic. On the other hand, contract services are expected to be lower than the previous
forecast, but this is due to plans to prioritize high-value services in the field of regenerative medicine
products.
With regard to profits, gross profit is expected to significantly exceed the previous forecast due to anincrease in net sales, mainly of research reagents, and a decrease in the cost of sales ratio due to a change
in the sales composition and an improvement in the production utilization rate, etc. Although selling,
general and administrative expenses will increase, the impact of the increase in gross profit will besignificant, and each profit item is expected to exceed the previous forecast, resulting in an increase inoperating profit and ordinary profit for the 12th consecutive fiscal year.

For the reasons stated above, net sales, operating profit, ordinary profit, and net incomeattributable to owners of the parent are each expected to exceed the previous forecasts,
and therefore the forecasts for the full fiscal year have been revised.
2. Revision to Dividend Forecast(1) Details of Revised Dividend Forecast
Dividend per share (Yen)Record date

End of 2nd quarter

Previous forecast

End of fiscal year

Total

8.00

8.00

9.00

9.00

8.00

8.00

(Disclosed on May 14, 2020)
Revised forecast
Actual amount for the current fiscal year
Actual amount for the previous fiscalyear (fiscal year ended March 31, 2020)

0.00
0.00

(2) Reason of the RevisionConsidering the management performance and financial statement comprehensively, Takara Bio
recognizes a basic policy aimed for profit contribution, positioning an important business
management issue to distribute profits to shareholders as well as enhancin g the internal reserves tostrengthen the research development activities in Bioindustry and Gene Therapy businesses.
Specifically, the dividends of surplus will be paid at around 20% of estimated profit calculated
without considering extraordinary income or loss in the consolidated financial statements.
Takara Bio decided to upwardly revise the forecasted year-end dividend for fiscal 2021 by of ¥1.00
per share from ¥8.00 to ¥9.00 under the revision of financial forecast and the shareholder return policy
shown above.
As for the year-end dividend for fiscal 2021, it will be resolved at the 19 th Annual General Meetingof Shareholders held in June 2021.

Forward-Looking Statements
Statements contained in these materials with respect to the Company's current plans, forecasts, strategies andbeliefs that are not historical facts are forward-looking statements about the future performance of the Companyand its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in lightof information currently available to it, but are based on a number of assumptions and beliefs derived frominformation that contains significant risks and uncertainties. Actual results may differ materially from these
forecasts due to various factors. Factors that could influence actual results include, but are not limited to,economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes inlaws and government systems, pressure from competitors' prices and product strategies, declines in selling
power of the Company's existing and new products, disruptions to production, violations of our intellectual
property rights, rapid advances in technology, and unfavorable verdicts in major litigation.